25 citations
,
February 2009 in “The Journal of Urology” Short-term finasteride treatment may lower some cell death factors in prostate cancer cells.
9 citations
,
November 2021 in “Infectious Agents and Cancer” Androgen deprivation therapy doesn't lower the risk of death from COVID-19 in prostate cancer patients.
9 citations
,
September 2014 in “Cancer Epidemiology, Biomarkers & Prevention” Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.
2 citations
,
November 2017 in “Biotechnology Letters” Researchers found four natural compounds that can change DHT levels in prostate cancer cells.
March 2011 in “European Urology Supplements” Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.
March 2011 in “European Urology Supplements” CEC levels may be a useful marker for predicting prostate cancer progression.
16 citations
,
January 2003 in “Nuclear Receptor Signaling” Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.
7 citations
,
October 2017 in “The Prostate” Baldness in men with prostate cancer is linked to higher levels of certain sex hormones, but chest hair density is not.
March 2011 in “European Urology Supplements” The document concludes that a new biosensor can efficiently detect prostate cancer cells and that standardized referrals help find significant cancers effectively.
3 citations
,
March 2018 in “BMC Cancer” Baldness, especially at the front, may lower the risk of testicular cancer by 31%, but its link to prostate cancer is unclear.
23 citations
,
May 2019 in “Expert Opinion on Therapeutic Patents” New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.
1 citations
,
January 2013 in “MedChemComm” PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
18 citations
,
January 1998 in “Endocrine” RU58841, a nonsteroidal anti-androgen, showed potential as a topical treatment for hair loss, increasing hair density, thickness, and length without systemic side effects in Stumptailed Macaques.
3 citations
,
December 2016 in “Canadian Urological Association journal” Men with more advanced male pattern baldness have a higher risk of prostate cancer and more severe disease.
August 2012 in “Expert Review of Dermatology” Men with early hair loss may have a higher risk of enlarged prostate and possibly prostate cancer due to shared hormonal factors.
10 citations
,
October 2012 in “Andrology” Prostate cancer can progress even with low testosterone due to internal hormone production in the tumor.
21 citations
,
June 2002 in “PubMed” The conclusion is that there might be a link between certain types of baldness and prostate cancer, which could be due to shared hormonal pathways.
March 2011 in “European Urology Supplements” Gene variation affects prostate issues and hair loss.
April 2022 in “Authorea (Authorea)” CT scans can find serious prostate cancer even when PSA levels are low.
14 citations
,
November 2008 in “Expert opinion on drug metabolism & toxicology” Finasteride helps treat prostate issues and may prevent prostate cancer in high-risk men.
27 citations
,
January 1984 in “Pharmacology & Therapeutics” Antiandrogens have important biological effects, but more research is needed to understand them fully and compare their effectiveness and side effects to other treatments.
18 citations
,
April 2001 in “Bioorganic & Medicinal Chemistry Letters” The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.
7 citations
,
October 2019 in “Bioorganic & medicinal chemistry” Analog 23 is a promising compound for prostate cancer treatment.
December 1998 in “Acta Crystallographica Section C-crystal Structure Communications” A new compound with strong antiandrogenic effects was found, potentially useful for treating conditions like acne and prostate cancer.
21 citations
,
February 2021 in “Frontiers in Endocrinology” Hormones affect prostate health and disease, with certain hormone imbalances linked to prostate cancer and benign prostatic hyperplasia.
72 citations
,
October 1998 in “Baillière's clinical endocrinology and metabolism” Long-term testosterone therapy can cause hormone suppression, affect prostate and heart health, and alter physical characteristics, but does not increase prostate cancer risk and needs more research for full risk assessment.
29 citations
,
October 1988 in “Journal of Steroid Biochemistry” Antiandrogens are effective for conditions like prostate cancer and skin issues, but more research is needed to confirm their benefits and minimize side effects.
4 citations
,
March 2018 in “PloS one” Men with less sun-sensitive skin have lower PSA levels, while men with more sun-sensitive skin have higher PSA levels.
24 citations
,
April 2014 in “Oncotarget” Minoxidil can reduce functions related to androgen receptors.
1 citations
,
January 2022 in “BMC Genomic Data” The study found that androgen receptors in skin cells mainly affect the focal adhesion pathway and control the caveolin-1 gene, with implications for new treatments for related diseases.